Advocates for Human Potential, Inc.

A Bureau of Justice Assistance (BJA) funded program provided by Advocates for Human Potential, Inc. (AHP)
in partnership with Treatment Alternatives for Safe Communities (TASC) and AdCare Criminal Justice Services (ACJS).


Jail-Based Medication-Assisted Treatment

Promising Practices Guidelines for Residential Substance Abuse Treatment

Role of Corrections Officers in Jail/Prison Substance Use Disorder Treatment Programs

Preventing, Detecting and Treating HIV/AIDS and Viral Hepatitis: Health Promotion and Risk/Harm Reduction in Substance Abuse Treatment

A Comprehensive Listing of What States Cover for Substance
Use Disorder, including Medications

New Manual on
Health Literacy

Once they obtain health coverage, RSAT participants need to maximize the benefits offered in terms of preventive and primary care to promote both better physical and behavioral health.


Other Prison/Jail MAT Manuals

Kentucky DOC Substance Abuse Medication Assisted Treatment Protocol
Rhode Island Vivitrol Manual
Rhode Island Suboxone SOP
Rhode Island Distribution of Suboxone Protocol
Massachusetts Department of Correction Medication Assisted Treatment Re-Entry Initiative (MATRI) Clinical Guidelines
Vermont MAT for Inmates: Work Group Evaluation Report and Recommendations
New Hampshire DOC MAT and Naltrexone Oral Augmentation Clinical Guidelines
Department of Vermont Health Access, Managed Care Entity, Vermont Buprenorphine Clinical Practice Guidelines, August 2015
Resolution of National Sheriffs’ Association on MAT
ACA and ASAM Joint Policy on OUD Rx in Justice System

Correctional MAT Videos

SAMHSA Video: Benefits and Cost Savings of MAT
Services in a Correctional Setting

This video features presentations from Jon Berge, SAMHSA, Mark Parrino, American Association for the Treatment of Opioid Dependence, Andrew Klein, RSAT TTA and Advocates for Human Potential, Kathleen Maurer, Connecticut DOC, and Kevin Pangburn, Kentucky DOC.

Montgomery County Corrections

Montgomery County, Maryland Department of Correction and Rehabilitation
video on that institution’s MAT Program

Massachusetts Department of Corrections

Brief descriptions of some Prison and Jail MAT Programs

Kentucky Prison, Massachusetts Prison, Philadelphia Jail, Rhode Island Prison,
West Virginia Prison, Wisconsin, Sacramento Jail, New Haven and Bridgeport Jails (Administered by state DOC), Kenton County, Kentucky Jail, Montgomery County, Maryland Jail, Barnstable County, Massachusetts Jail, Middlesex County, New York City Jail, and Salt Lake City Jail

Medication Assisted Treatment Programs In Vermont State Corectional Facilities

This report reviews state correctional MAT programs in VT, MA, NH, MO, RI & KY, and includes the latest cost and recidivism data from most of them.


Report on New Hampshire DOC MAT in Custody
Naltrexone Program

"A Rehab Jail for Heroin Addicts" in Franklin County Massachusetts

Franklin County and the Greenfield, Massachusetts community addresses the opioid crisis with an innovative approach to treatment. The Franklin County Jail is one of the only corrections facilities in the country offering suboxone to its clients.

RSAT Jail Program Tour

What Inmates Tell us About RSAT

  • Title: Overdose Prevention

  • Date: January 30, 2019

  • Click here for webinar and registration information

  • Providing MAT to Prisoners Raises Questions

    Dr. Andrew Klein discusses the implications of the recent Massachusetts ruling ordering a jail to continue to provide methadone to an entering individual. The real question is how should jails and prisons provide opioid medications to all incarcerated persons with opioid use disorders?

  • Medicaid Coverage of Medication-Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose

    This SAMHSA publication details coverage for MAT medications and Naloxone. All states reimburse for at least some of the MAT medications although 8 don’t cover methadone for MAT, just for pain relief. Fewer than 70% cover implant and injectable buprenorphine. Many include certain constraints on obtaining the medication. Some innovative programs are highlighted such as Missouri which has begun the process of integrating MAT into all SUD treatment in the state, requiring any SUD treatment provider that contracts with the state to offer MAT either directly or by referral. The state of Washington has implemented a pilot involving a telemedicine project, Flex Care, so that 200 patients in rural coastal Washington who previously had no access to MAT for their opioid dependence disorder now receive MAT under the Flex Care treatment model.

  • Fentanyl Now The no. 1 Opioid OD Killer

    Although cocaine and heroin remain most popular street drugs, fentanyl is involved in more overdose deaths. Between 2013 and 2016, overdose deaths involving fentanyl increased 113% per year. Over the past several years, heroin and cocaine mixed with fentanyl have become more common, which may account for the combination of drugs seen on death certificates. methamphetamine. In 2011, oxycodone ranked first. From 2012 to 2015, it was heroin, and in 2016, fentanyl. Cocaine consistently was the second or third drug most common in overdoses during the entire period.

  • Prescription Mobile Medical App cleared as component of Opioid Use Disorder Treatment

    The U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase treatment retention in an outpatient program for individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive behavioral therapy intended to be used in addition to outpatient treatment under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. Although reSET-O did not reduce positive drug screens, it did significantly increase treatment retention. Using internet-based or mobile apps in conjunction with treatment for substance use disorders is not a new idea. There are many studies going back over 10 years that have shown promising outcomes in using technology based cognitive-behavioral treatment sessions and/or community reinforcement approach to enhance as well as reduce traditional counselor based treatment sessions. Evidence-based interventions will continue to be designed to improve executive function and be delivered through the use of mobile apps and, coupled with their high program consistency and participant enjoyment, appear to be a logical choice for repairing cognitive dysfunction.

  • Best Practices for Successful Reentry for People Who Have Opioid Addiction

    This new publication from Council of State Government Justice Center outlines major reentry activities. It describes best practices for correction departments, community-based behavioral health agencies, and probation and parole to ensure reentry is safe and successful for people with opioid addictions.

  • Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States

    Overshadowed by opioids, meth is back with a vengeance. Study finds amphetamine use is skyrocketing in United States. Hospitalizations up 245% from 2008 to 2015. Poses renewed challenge for RSAT programs.

  • MA Jail Ordered to Continue Methadone for Entering Inmate

    Order from Federal District Court requiring Massachusetts jail to continue methadone for individual entering jail for 60 day sentence for operating after suspension. Defendant had failed to remain abstinent on buprenorphine and naltrexone but had succeeded for past two years on methadone. Sheriff had argued that medical detox and in house drug treatment as well as access to naltrexone was sufficient to address defendant’s needs without compromising institutional security by allowing the introduction of methadone the jail was not equipped to dispense.

  • Long Stigmatized, Methadone Clinics Multiply in Some States

    Access to methadone maintenance is growing, but Alabama, Arkansas, Idaho, Illinois, Iowa, Kentucky, Louisiana, Nebraska, North Dakota, South Carolina, Tennessee, Texas and Wyoming do not allow Medicaid reimbursement for methadone treatment. Much lower number of doctors prescribe buprenorphine of opioid addiction than anticipated. Many obtain licenses to prescribe buprenorphine (requires 8 hour course) but treat only existing patients and are not interested in adding new patients with opioid use disorder. This means that jail and prisons that institute MAT programs that provide agonist medications have to do their homework to connect exiting individuals with available methadone clinics or physicians and medical personnel willing to treat them with buprenorphine.

  • Large randomized trial finds disappointing effects for federally-funded (Second Chance) programs to facilitate the re-entry of prisoners into the community. A new approach is needed.

    Study says it is very possible that some reentry programs were effective but their effect was diluted by others that were ineffective or harmful, resulting in an average effect near zero. It suggests evidence-based reforms to Second Chance Act that focus on a central goal: identifying a subset of specific re-entry strategies rigorously shown to produce important effects on recidivism and other key outcomes.

  • Managing Comorbid Opioid and Alcohol Use Disorder

    Lest we forget, more people die from alcoholism every year than opioids (88,000 vs 49,000). Because both alcohol and opioids have central nervous system depressant effects, so that comorbid AUD and OUD have a greater chance of inducing respiratory depression and overdose than either disorder alone. Article discusses need to treat both.

  • Prescription Databases May Miss Opioid-Benzo Combinations

    A new 2018 Quest Diagnostics analysis revealed that prescriptions databases may be missing concurrent opioid and benzodiazepine in patients drug tests. Among a selected sample of patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least one benzodiazepine or opioid that was not prescribed. The Quest Diagnostics analysis was based on 456,675 sets of test results from 276,953 patients in 50 states and the District of Columbia in 2017.

  • Why You Shouldn’t Dismiss The Risk of Marijuana Addiction

    The National Survey on Drug Use and Health (NSDUH) from 2016 found that about 4 million people 12 and older meet the classification for a marijuana use disorder. That’s nearly 11 percent of the 37.6 million people 12 and older who reportedly used marijuana in 2016.

  • As America’s Jails Become Warehouses For Mentally Ill

    No other country in the world is using its jails as its primary response to mental illness.

  • NASTAD - Pharmaceutical Company Patient Assistance and Cost-sharing Assistance Programs: Hepatitis

    This NASTAD website describes Patient Assistance and Cost-sharing Assistance Programs for medication to treat Hepatitis for people with low incomes who do not qualify for Medicaid, Medicare or AIDS Drug Assistance Programs.

  • Pre-release Injectable Naltrexone Improves HIV treatment too.

    A new study finds that those released on injectable naltrexone are more likely to maintain or improve their HIV viral load suppression, indicating all important HIV medication compliance. Typically, the period of time right after persons are released from jail is chaotic, associated with both opioid overdoses and loss of HIV care. The injection, by reducing cravings during this critical period, appears to allow individuals to concentrate on self-care in general. Springer, S. A. et. al. (2018). Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial, Journal of Acquired Immune Deficiency Syndromes. 78(1):43-53

  • California Reentry Guide

    Reentry Health Policy Project’s Meeting the Serious Health and Behavioral Needs of Prison and Jail Inmates Returning to the Community identifies state and county-level policies and practices to deliver effective care to people who are reentering California communities. It focuses on the following issue areas: 1) Eligibility establishment to receive care; 2) Care coordination; 3) Maximizing federal financial participation, primarily through the Affordable Care Act; 4) Release of information; 5) Residential and outpatient treatment capacity; 6) Housing; and 7) Evaluation.

  • Promising Practices Archive

Information on Effective Cognitive Behavioral Approaches

MAT Resources and Research

Substance Abuse Facilities-Opioid Treatment Services,
SAMHSA Feb. 2017

Map of Opioid Treatment Providers

SAMHSA’s Pocket Guide to Medication-assisted Treatment for Opioid Use Disorders

Link to PDF:

Link to SAMHSA Store page on this item:

FDA Newly Issued ‘Boxed’ warning on the dangers of combining opioids and benzodiazepines

Link to the FDA Drug Safety Announcement:

Link to PDF of Safety Announcement:

Tennessee Health Department Finds Some Overdose Deaths Associated With Buprenorphine

Opioid Treatment Drugs Have Similar Outcomes Once Patients Initiate Treatment

This NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. It is the second that now finds the two medications work equally well although one is an opioid substitute and the other an opioid (and alcohol) blocker.

Participate in our forum!

Our RSAT program features a modified therapeutic community. We would like to involve the correction officers as much as possible without compromising their essential security and other roles. Are there other RSATs that have successfully integrated CO's into their TC programming? How did they do it?